An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia.
David J KuterHasan A AlbitarScott E OlitskyMarianne S ClancyVivek N IyerPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2020)
Systemic bevacizumab is widely used to treat bleeding in HHT with excellent physician-reported effectiveness and safety. There is considerable variation in maintenance treatment practices and thresholds for initiation of bevacizumab among HHT centres.